Charles River and Pluristyx partner on human pluripotent stem cells
The partnership agreement provides Charles River with broad access to highly characterised stem cell lines including embryonic stem…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
21 Feb 24
The partnership agreement provides Charles River with broad access to highly characterised stem cell lines including embryonic stem…
21 Feb 24
The CTDMO will now begin the analytical testing and manufacturing of the FDA-approved tumour-derived autologous T cell immunotherapy…
20 Feb 24
The EC approval of Velsipity was supported by results from the Phase 3 ELEVATE UC registrational programme, which…
20 Feb 24
The Barcelona-based drugmaker now has the rights to develop and market the monoclonal antibody in certain fields, including…
19 Feb 24
The FDA approval is based on data from the Phase 3 OUtMATCH study, which showed a high proportion…
19 Feb 24
Under the agreement, Apotex will seek market approval in Canada for VEVYE, IHEEZO, and ZERVIATE in Canada, and…
Patient CarePharmaceuticals and MedicinesPartnerships and Licensing Agreements
19 Feb 24
The approval was based on the findings from the FLAURA2 trial in which Tagrisso with chemotherapy reduced the…
19 Feb 24
Everest Medicines is a biopharmaceutical company focused on developing, manufacturing and commercializing transformative pharmaceutical products and vaccines that…
16 Feb 24
Under the agreement, the firms intend to combine Xyphos' ACCEL technology and Kelonia's iGPS to create in vivo…
16 Feb 24
The partnership will combine Intellia's patented CRISPR-based gene editing platform with ReCode's Selective Organ Targeting (SORT) lipid nanoparticle…